BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 18024953)

  • 1. Emergence of Candida tropicalis resistant to caspofungin.
    Pasquale T; Tomada JR; Ghannoun M; Dipersio J; Bonilla H
    J Antimicrob Chemother; 2008 Jan; 61(1):219. PubMed ID: 18024953
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of the "Dip Effect" Phenomenon in Antifungal Susceptibility Testing of Candida spp. against Echinocandins by Use of Gradient Concentration Strips.
    Siopi M; Tsala M; Siafakas N; Zerva L; Meletiadis J
    J Clin Microbiol; 2015 Nov; 53(11):3654-9. PubMed ID: 26338855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Caspofungin-non-susceptible Candida isolates in cancer patients.
    Kofteridis DP; Lewis RE; Kontoyiannis DP
    J Antimicrob Chemother; 2010 Feb; 65(2):293-5. PubMed ID: 20016020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful treatment of an infant infected with refractory C. parapsilosis with caspofungin.
    Ozkaya-Parlakay A; Tezer H; Kazmacan T; Gulhan B; Unal S
    J Trop Pediatr; 2014 Aug; 60(4):329-30. PubMed ID: 24567311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment with caspofungin of Candida tropicalis endocarditis resistant to fluconazol].
    del Castillo M; Wainsztein N; Klein F; Manganello S; Orellana N
    Medicina (B Aires); 2004; 64(2):152-4. PubMed ID: 15628305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies.
    Garcia-Effron G; Kontoyiannis DP; Lewis RE; Perlin DS
    Antimicrob Agents Chemother; 2008 Nov; 52(11):4181-3. PubMed ID: 18794386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of Echinocandins in Candida Biofilm-Related Vascular Catheter Infections: In Vitro and In Vivo Model Systems.
    Ghannoum M; Roilides E; Katragkou A; Petraitis V; Walsh TJ
    Clin Infect Dis; 2015 Dec; 61 Suppl 6():S618-21. PubMed ID: 26567279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Invasive infection in an acute myeloblastic leukemia patient due to triazole-resistant Candida tropicalis.
    de Carvalho Parahym AM; da Silva CM; Leão MP; Macario MC; Filho GA; de Oliveira NT; Neves RP
    Diagn Microbiol Infect Dis; 2011 Nov; 71(3):291-3. PubMed ID: 21924853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First Case of Echinocandin-Resistant Candida albicans in Korea.
    Park MS; Park JE; Song DJ; Huh HJ; Park S; Kang CI; Shin JH; Lee NY
    Ann Lab Med; 2017 Nov; 37(6):556-558. PubMed ID: 28841000
    [No Abstract]   [Full Text] [Related]  

  • 10. Frequency of the Paradoxical Effect Measured Using the EUCAST Procedure with Micafungin, Anidulafungin, and Caspofungin against Candida Species Isolates Causing Candidemia.
    Marcos-Zambrano LJ; Escribano P; Sánchez-Carrillo C; Bouza E; Guinea J
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27799221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stepwise development of a homozygous S80P substitution in Fks1p, conferring echinocandin resistance in Candida tropicalis.
    Jensen RH; Johansen HK; Arendrup MC
    Antimicrob Agents Chemother; 2013 Jan; 57(1):614-7. PubMed ID: 23089761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of micafungin for the treatment of invasive candidiasis and candidaemia in patients with neutropenia.
    Chandrasekar P; Sirohi B; Seibel NL; Hsu JW; Azie N; Wu C; Ruhnke M
    Mycoses; 2018 May; 61(5):331-336. PubMed ID: 29364548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Successful treatment with caspofungin of an invasive candidosis resistant to liposomal amphotericin B in a neutropenic patient].
    Rome A; André N; Michel A; Coze C; Gentet JC; Bernard JL
    Arch Pediatr; 2006 Dec; 13(12):1556-7. PubMed ID: 17049216
    [No Abstract]   [Full Text] [Related]  

  • 14. Increasing incidence of Candida parapsilosis candidemia with caspofungin usage.
    Forrest GN; Weekes E; Johnson JK
    J Infect; 2008 Feb; 56(2):126-9. PubMed ID: 18082269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Caspofungin disk diffusion breakpoints and quality control.
    Brown SD; Traczewski MM
    J Clin Microbiol; 2008 Jun; 46(6):1927-9. PubMed ID: 18400918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Caspofungin.
    Parakh A; Dubey AP; Samanta D
    Indian Pediatr; 2008 Nov; 45(11):905-10. PubMed ID: 19029563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Caspofungin use in patients with invasive candidiasis caused by common non-albicans Candida species: review of the caspofungin database.
    Colombo AL; Ngai AL; Bourque M; Bradshaw SK; Strohmaier KM; Taylor AF; Lupinacci RJ; Kartsonis NA
    Antimicrob Agents Chemother; 2010 May; 54(5):1864-71. PubMed ID: 20231388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Micafungin therapy in a critically ill, morbidly obese patient.
    Zomp A; Bookstaver PB; Ahmed Y; Turner JE; King C
    J Antimicrob Chemother; 2011 Nov; 66(11):2678-80. PubMed ID: 21810839
    [No Abstract]   [Full Text] [Related]  

  • 19. Candida tropicalis in human disease.
    Chai LY; Denning DW; Warn P
    Crit Rev Microbiol; 2010 Nov; 36(4):282-98. PubMed ID: 20883082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo studies with a Candida tropicalis isolate exhibiting paradoxical growth in vitro in the presence of high concentration of caspofungin.
    Bayegan S; Majoros L; Kardos G; Kemény-Beke A; Miszti C; Kovacs R; Gesztelyi R
    J Microbiol; 2010 Apr; 48(2):170-3. PubMed ID: 20437148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.